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Objectives This study sought to assess whether renal sympathetic denervation (RSDN) can be
achieved using an off-the-shelf saline-irrigated radiofrequency ablation (RFA) catheter typically em-
ployed for cardiac tissue ablation.
Background RSDN using a specialized solid-tip RFA catheter has recently been demonstrated to
safely reduce systemic blood pressure in patients with refractory hypertension. For cardiac tissue
ablation, RFA technology has evolved from nonirrigated to saline-irrigated ablation electrodes to
improve both safety and effectiveness.
Methods Ten patients with resistant hypertension underwent renal angiography, followed by bilat-
eral RSDN with a saline-irrigated RFA catheter. Ambulatory blood pressure recordings (24 h) were
obtained at baseline, 1, 3, and 6 months after the procedure. Repeat renal angiography was per-
formed during follow-up to assess for arterial stenosis or aneurysm. In 5 patients, pre- and post-
procedural serum measures of renal function and sympathetic activity were obtained: aldosterone;
metanephrine; normetanephrine; plasma renin activity; and creatinine.
Results Over a 6-month period: 1) the systolic/diastolic blood pressure decreased by 21/11 mm Hg;
2) all patients experienced a decrease in systolic blood pressure of at least 10 mm Hg (range 10 to 40
mm Hg); 3) there was no evidence of renal artery stenosis or aneurysm at repeat angiography; and 4)
there was a signiﬁcant decrease in metanephrine (12  4, p  0.003), normetanephrine (18  4,
p  0.0008), and aldosterone levels (60  33 ng/l, p  0.02) at 3 months. There was no signiﬁcant
change in plasma renin activity (0.2 mg/l/hod, p  0.4). There was no signiﬁcant change in serum cre-
atinine (1 mmol/l, p  0.4).
Conclusions These data provide the proof-of-principle that RSDN can be performed using an off-
the-shelf saline-irrigated RFA catheter. (J Am Coll Cardiol Intv 2012;5:758–65) © 2012 by the
American College of Cardiology Foundation
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759Despite the development of antihypertensive drugs designed
to block various avenues of the complex renal-cardiovascular
circuit, hypertension remains a considerable, and poorly
managed, medical, social, and economic burden (1). For
various reasons, including the considerable costs of treat-
ment, up to 65% of hypertensive patients have untreated
and/or uncontrolled blood pressure (BP). Of those, 10%
have resistant hypertension—defined as elevated BP refrac-
tory to treatment with 3 antihypertensive agents of dif-
erent classes.
See page 766
From a pathophysiological perspective, in essential hy-
pertension there is increased sympathetic drive from the
kidneys, as measured by increased afferent firing of renal
sympathetic nerves, as well as an increased rate of renal and
whole-body norepinephrine spillover (2,3). Increased sym-
pathetic nervous system (SNS) efference to the renal system,
in turn, promotes Na reabsorption via nephritic alpha1
adrenoreceptors and activation of the renin-angiotensin-
aldosterone system—ultimately leading to volume expan-
sion resulting in sustained elevations in systemic BP. Based
in part on the surgical experience from over a half-century
ago that thoracolumbar sympathectomy could normalize BP
in patients with malignant hypertension (4,5), the Symplic-
ity HTN (Renal Sympathetic Denervation in Patients with
Treatment-Resistant Hypertension) trials recently demon-
strated that the sympathetic nerve fibers along the renal
arterial vasculature can be targeted for catheter ablation
using a specialized radiofrequency ablation (RFA) catheter
(6–8). Although spurring a great deal of scientific and
clinical excitement, 2 important limitations of this approach
are: 1) this specialized first-generation catheter for renal
sympathetic denervation (RSDN) is a solid-tip RFA cath-
eter that, in theory, may promote char formation; and 2) the
specialized catheter used in this study is not yet commer-
cially available in many countries.
By contrast, there is now over a decade of pre-clinical and
clinical experience with the use of saline-irrigated RFA
catheters for the ablation of cardiac arrhythmias. In theory,
saline-irrigation has the advantage of being less likely to
cause thrombus/char formation at the ablation site (9,10).
Furthermore, saline irrigation is known to project ablation
lesions to deeper within the tissue—a potential advantage
during RSDN, given the adventitial location of the renal
sympathetic nerves. Although these saline-irrigated RFA
catheters have been employed widely in the ablation of
cardiac chambers and the great vessels (e.g., aorta, pulmo-
nary artery, pulmonary veins), there are no published data
on the safety and efficacy of RSDN with off-the-shelf RFA
catheters.Methods
All procedures were performed after obtaining written
informed consent according to the institutional guidelines at
Homolka Hospital, Prague, Czech Republic.
Patient characteristics. This first-in-man clinical experience
ith a saline-irrigated RFA catheter for RSDN occurred in
atients with a history of chronic hypertension (systolic BP
140 mm Hg) refractory to 3 antihypertensive medica-
ions (including at least 1 diuretic). Patients were excluded
f they had a known secondary cause of hypertension,
stimated glomerular filtration rate 45 ml/min, type 1
iabetes or known renovascular abnormalities (renal artery
tenosis, previous renal artery stenting or angioplasty).
Baseline measurements. Because of the well-described phe-
nomenon of “white coat hypertension,” all patients under-
went 24-h ambulatory blood pressure monitoring (ABPM)
with an oscillometric device that obtained BP readings every
30 min during the day and every 60 min at night. In
addition, before the delivery of any radiofrequency energy,
the following baseline measurements were obtained from
all patients: 1) serum creatinine;
2) plasma renin activity; 3) aldo-
sterone; 4) metanephrine; and
5) normetanephrine.
Renal sympathetic denervation.
Procedures were performed un-
der either deep sedation or gen-
eral anesthesia. After standard
femoral vascular access, a pigtail
catheter was advanced to the
abdominal aorta, and contrast
angiography was performed to
localize and assess the renal ar-
teries for accessibility and appropriateness for RSDN. An
appropriate anatomy was one in which the renal arteries
were identified, the takeoff of each renal artery from the
aorta was amenable to catheter cannulation, and there was
no significant observable renal arterial atherosclerosis where
ablation would be performed.
Once the anatomy was deemed acceptable, a 3.5-mm-tip
internally irrigated RFA catheter (Celcius Thermocool,
Biosense Webster, Diamond Bar, California) was advanced
under fluoroscopic guidance. A flexible 45-cm, 8-F sheath
(Arrow International, Inc., Reading, Pennsylvania) was
advanced over the ablation catheter to engage the renal
artery ostium and allow for contrast visualization of the
renal artery during catheter manipulation. The ablation
catheter was then maneuvered within the renal artery to
allow energy delivery in a circumferential, longitudinally
staggered manner to minimize the chance of renal artery
stenosis. Energy titration was performed to achieve a 10% to
Abbreviations
and Acronyms
ABPM  ambulatory blood
pressure monitoring
BP  blood pressure
RFA  radiofrequency
ablation
RSDN  renal sympathetic
denervation
SNS  sympathetic nervous
system20% drop in impedance at each location (11). No more than
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7607 ablation lesions, lasting 30 to 90 s each, were placed
within each renal artery.
Follow-up. All patients underwent follow-up renal angiog-
raphy to assess for renal artery stenosis. At this time,
5 patients additionally underwent repeat blood draws to
measure serum creatinine, plasma renin activity, aldoste-
rone, metanephrine, and normetanephrine. Additionally, all
patients underwent: 1) repeat 24-h ABPM; and 2) were
seen in the office at 1, 3, and 6 months post-procedure for
assessment of adverse events and medication changes.
Statistical analysis. Continuous variables are expressed as
ean SD. Descriptive statistics were applied to assess the
Table 1. Baseline Patient Characteristics (N  10)
Demographic information
Age, yrs 61 12
Men, % 80
Body mass index, kg/m2 33 5
Relevant medical history
Hypertension 10 (100%)
Diabetes mellitus 3 (30%)
Atrial ﬁbrillation 1 (10%)
CAD 2 (20%)
Obesity 8 (80%)
Dyslipidemia 6 (60%)
Antihypertensive drugs
ACE inhibitor 10 (100%)
Angiotensin receptor blocker 8 (80%)
Beta-blocker 8 (80%)
Calcium-channel blocker 9 (90%)
Diuretic 10 (100%)
Centrally acting antihypertensive 10 (100%)
Values are mean SD or n (%).
ACE angiotensin-converting enzyme; CAD coronary artery disease.
Table 2. Procedural Characteristics
Patient #
No. of Lesions Avg. Lesion
Duration
(s)
Total RF
(s)
Temp.
Max.
(°C)
Po
A
(LRA RRA
1 5 6 30 333 37 1
2 4 4 15 117 36 1
3 4 4 21 169 42 1
4 5 1 24 145 37 1
5 6 5 30 328 43 1
6 6 7 30 390 37 1
7 2 3 24 149 39 1
8 6 5 30 330 40 1
9 6 4 25 254 37 1
10 4 4 25 203 35 1
Average 5 1 4 2 26 6 242 98 39 3 15
Minimum 2 1 15 117 35 1
Maximum 6 7 30 390 43 1LRA left renal artery; RF radiofrequency; RRA right renal artery; Temp. temperature.ajor endpoints: 1) change in BP, as obtained from ABPM;
) freedom from procedural complications; 3) a decrease in
enal SNS breakdown products; and 4) freedom from
hange in renal function, as measured by serum creatinine
evels.
esults
Patient characteristics. This prospective, consecutive series
consisted of 10 hypertensive patients refractory to treatment
with 6.7  1 medications (range 4 to 9), including diuretic
therapy. The mean age of the patient cohort was 61  12
years; the mean body mass index was 33.2 5 kg/m2 (range
26.9 to 46.2 kg/m2) (Table 1).
Ablation procedure. Renal angiography revealed a highly
ariable and often tortuous arterial anatomy. Neverthe-
ess, the vasculature was amenable to ablation in all
atients; in 1 patient, ablation was limited to 1 lesion
ithin the right renal artery because of the presence of
therosclerosis. There was no pre-existing renal artery
tenosis in any patient.
In the patient cohort, 91 ablation lesions were delivered.
verall, 5 1 (range 2 to 6) and 4 2 (range 1 to 7) lesions
ere delivered to the left and right renal artery, respectively
Table 2). The mean duration of ablation was 242  98 s of
FA per patient (range 117 to 390 s). See Table 2 for a
etailed account of ablation parameters and fluoroscopy
uration/exposure. During radiofrequency energy delivery,
ain was universally experienced; this discomfort lasted only
he duration of ablation and was managed successfully with
ntravenous benzodiazepines or propofol.
Safety. There were no acute procedural adverse events. How-
ver, there were several instances of ablation-related luminal
rterial irregularities—presumably renal arterial spasm; how-
Power
Max.
(W)
Start
Impedance
()
Mean
Impedance 
()
Fluoroscopy
Time
(min)
Radiation
Exposure
(Gym2)
17 163 9 23 10,301
20 159 18 19 8,306
13 171 10 9 5,487
19 217 24 12 8,883
12 159 10 10 4,639
16 201 16 13 6,641
16 172 11 18 7,876
13 206 23 8 2,785
15 246 18 14 4,288
20 221 24 15 9,482
17 3 192 31 16 6 14 5 6,869 2,495
13 159 9 8 2,785
20 246 24 23 10,301wer
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761ever, none of these was flow-limiting. When encountered,
intra-arterial nitroglycerin was typically administered. All
patients were discharged within 24 h of the procedure.
During repeat renal angiography at 3 months after the
procedure, there were no instances of renal arterial
narrowing or stenosis or aneurysmal dilation; indeed,
there were not even any instances of luminal irregulari-
ties. All patients were free from adverse events. As
determined by baseline and 3-month serum creatinine
levels, there was also no significant change in renal
function (71  20 ng/l vs. 70  16 mol/l, respectively:
 1 mmol/l, p  0.4).
Blood pressure. As determined by 24-h ABPM, the mean
aseline BP was 158  16/88  15 mm Hg on 6.7  1
antihypertensive medications (range 4 to 9). All patients
were taking at least 1 diuretic and at least 1 centrally acting
antihypertensive drug; additionally, 8 patients were taking
an angiotensin-converting enzyme -inhibitor, 8 an angio-
tensin receptor blocker, 7 a beta-blocker, and 8 a calcium-
channel blocker.
During repeat 24-h ABPM at 1, 3, and 6 months after
the procedure, significant changes from baseline were ob-
served at all time points (Figs. 1 and 2). At 1 month, the
mean BP was 152  14/83  13 mm Hg, indicating a
hange of 6  4 mm Hg in systolic BP (range 1 to 15
m Hg; p  0.002) and 4  5 mm Hg (range 5 to 12
m Hg; p  0.02) in diastolic BP. BP changes were more
ramatic at 3 months: the BP was 136  12/75  13 mm Hg,
ndicating a change from baseline of 22  11 mm Hg in
Figure 1. Catheter Positioning During Renal Sympathetic Denervation
(A) Contrast injection into the abdominal aorta identiﬁes the locations and nu
ter (white arrow at tip) placed within the right renal artery, the vascular shea
is injected to visualize the vessel. Then, the catheter is serially positioned alon
renal artery to deliver radiofrequency energy.ystolic BP (range 27 to 40 mm Hg; p  0.0001) and
13  6 mm Hg (range 4 to 27 mm Hg; p  0.0001)
n diastolic BP. These BP changes were sustained at 6
onths. The BP was 135  8/76  8 mm Hg, indicating
change from baseline of 21  15 mm Hg in systolic BP
range10 to40 mm Hg; p 0.003) and11 9 mm Hg
range 0 to 26 mm Hg; p  0.005) in diastolic BP. On a
er-patient basis, significant (10 mm Hg) decreases in
ystolic BP were observed in all patients.
By 6 months, because of sustained decreases in systemic
P, all patients were able to decrease the dosage of at least
medication. In addition, 9 of 10 patients discontinued at
east 1 medication altogether (mean number of drugs at 6
onths: 5  1 drug; range 3 to 6). By contrast, despite
ignificant decreases in BP, all 10 patients continued on
ntihypertensive therapy at 6 months, including diuretics in
ll patients, centrally acting antihypertensive drugs in 9
atients, angiotensin-converting enzyme inhibitors in 8
atients, angiotensin receptor blockers in 6 patients, beta-
lockers in 6 patients, and calcium-channel blockers in 6
atients (Fig. 3).
Renal and sympathetic hormone activity. Five patients un-
derwent baseline and 3-month blood sampling for renal
hormones. A significant decrease was observed in the levels
of SNS metabolites, including metanephrines (  12 
4, p  0.003) and normetanephrines (  18  4, p 
0.0008) (Table 3). There was also a significant decrease in
aldosterone levels (  60 33 ng/l, p 0.02). Changes
of renal arteries. (B) With the saline-irrigated radiofrequency ablation cathe-
ck arrow at tip) is advanced over the catheter into the artery, and contrast
superior (C), anterior (D), posterior (E), and inferior (F) aspects of the rightmber
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762in the plasma renin activity were not significant: (  0.2
mg/l/hod, p  0.4).
Discussion
This study demonstrated that renal sympathetic denervation
with an externally irrigated RFA catheter is both safe and
effective in a series of patients with drug-resistant, systemic
hypertension. In addition to no acute procedural complica-
tions, repeat angiography at 3 months following ablation
indicated the absence of renal arterial stenosis in all patients.
As determined by 24-h ABPM, significant (10 mm Hg)
decreases in systolic BP occurred in all patients at 6 months.
In the total patient cohort, a statistically significant decrease
was observed in systemic BP at 1, 3, and 6 months after the
procedure, along with concurrent, statistically significant de-
creases in blood levels of renal hormones—metanephrines,
normetanephrines, and aldosterone.
Previous studies. The initial clinical studies demonstrating
the proof-of-principle that catheter-based RSDN can sig-
nificantly decrease the BP in patients with refractory hyper-
tension were performed using a specialized solid-tip RFA
catheter (7,8). The first, Symplicity HTN-1, was a nonran-
domized study employing this specialized RFA catheter in
45 drug-resistant hypertensive patients; the baseline office BP
(177 20 mm Hg/101 15 mm Hg, on 4.7 antihypertensive
medications) decreased by a mean of 27/17 mm Hg at 1 year.
Figure 2. Cohort BP Changes From Baseline at 1, 3, and 6 Months
Shown are the decreases in mean systolic and diastolic blood pressure (BP), as
As compared to baseline, the decrease in systolic/diastolic BP at 1, 3, and
21  15/11  9 mm Hg, respectively.There was both a concurrent 47% reduction in renal snoradrenaline spillover and a 66% decrease in muscle SNS
activity. Most importantly, this favorable BP decrease was
recently reported to be maintained over 2 years (8).
Symplicity HTN-2 also evaluated RSDN in patients with
refractory hypertension, but this was a randomized clinical
trial. In this study of 106 randomized patients, the 6-month
office BP in the denervation group decreased by 32/12 mm Hg
(baseline of 178/96 mm Hg, p  0.0001), whereas they did
ot differ from baseline in the control group (change of 1/0
m Hg, baseline 178/97 mm Hg, p  NS). From an
ndividual perspective, 41 of 49 patients (84%) in the renal
enervation group experienced a 6-month BP decrease of
10 mm Hg. Importantly, no serious procedure-related
dverse events were noted.
Symplicity HTN-2 was limited by the absence of a true
lacebo control because patients were not blinded to their
reatment assignment. However, both the magnitude of the
elative clinical benefit observed in the RSDN group and the
echanistic data confirming the pathophysiological ratio-
ale for improved BP underlie the significant enthusiasm
nd optimism for the role of RSDN in refractory hyper-
ension. Indeed, there is also significant scientific interest
nd active clinical investigation in the potential role for
SDN in other pathological states characterized by SNS
veractivity, such as type 2 diabetes or metabolic syn-
rome, congestive heart failure, cardiac arrhythmias, and
mined by 24-h ambulatory blood pressure monitoring at 1, 3, and 6 months,
onths were 6  4/4  5 mm Hg, 22  11/13  6 mm Hg, anddeter
6 mleep apnea.
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763Radiofrequency ablation technology. The specialized RFA
catheter employed in the Symplicity HTN-1 and Symplicity
HTN-2 trials was critical to establishing the feasibility and
efficacy of catheter-based RSDN. But based on the wealth
of experience in cardiac electrophysiology using radiofre-
quency energy to ablate cardiac arrhythmias, it would be
best to view this solid-tip radiofrequency catheter as a
first-generation ablation system for several reasons. First,
with a solid-tip catheter, as energy is being delivered from
the ablation electrode to the tissue, the heated tissue in turn
heats the electrode with which it is in contact. This creates
the potential for char formation on the electrode—the
probability of which increases with increasing temperatures
(9,10). Second, during radiofrequency energy delivery, heat-
ing is greatest at the tissue-electrode interface, which has a
tendency to both limit the depth of the lesion and maximize
the amount of damage to the endothelium.
Figure 3. Antihypertensive Medications at Baseline and 6 Months After Pr
(A) This chart indicates the mean number of antihypertensive medications for
played adjacent to the error bar. (B) This chart indicates the mean dose equiv
medication. This composite number reﬂects both the discontinuation of a dru
fraction of the baseline dose; for example, the baseline dosage of 10 mg equa
0.5 U of drug. ACE-I  angiotensin-converting enzyme inhibitor; ARB  angio
sive; CCB  calcium-channel blocker.
Table 3. Average Measurements at Renal Sampling (n  5)
Pre Post  p Value
Renin 0.8 0.3 0.6 0.4 0.2 0.6 0.40
Aldosterone 111 40 52 14 60 33 0.02
Metanephrine 36 12 24 9 12 4 0.003
Normetanephrine 67 22 49 21 18 4 0.0008Values are mean SD.Whereas temperature monitoring of the ablation elec-
trode during solid-tip RFA can somewhat ameliorate some
of these concerns, it is clear that the safest and most effective
approach to radiofrequency energy delivery is with saline
irrigation. By actively cooling the ablation electrode during
RFA, it is possible to both increase the point of greatest
heating to below the surface of the tissue and minimize the
possibility of char formation because the temperature of the
ablation electrode can be limited to 45°C by the saline
irrigation. These advantages to saline irrigation are signifi-
cant enough that most left-sided cardiac ablations are now
performed using irrigated ablation catheters (10).
Because saline-irrigated RFA catheters specialized for
RSDN procedures do not yet exist, we employed an
off-the-shelf saline-irrigated electrophysiology ablation
catheter for RSDN in this study. As expected, the amount
of energy delivered is higher than was used with the
specialized catheter because the size of the irrigated ablation
electrode is significantly larger and in addition to cooling
the ablation electrode, the saline carries some current away
from the catheter. Accordingly, energy delivery using the
irrigated catheter was titrated according to the level of
impedance drop—a strategy almost universally employed
during cardiac ablation—as the acute impedance drop dur-
ing catheter ablation is a direct reflection to the magnitude
re
atient cohort at baseline and 6 months; the mean number of drugs is dis-
f antihypertensive medications, broken down by type of antihypertensive
ell as a decrease in dosage. A dose decrease at 6 months was reﬂected as a
of drug so if the dose was decreased to 5 mg at 6 months, this counts as
receptor blocker; BB  beta-blocker; CAH  centrally acting antihyperten-ocedu
the p
alent o
g, as w
ls 1 U
tensinof the volume of tissue being heated (11).
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764Even though other cardiovascular applications have elu-
cidated the advantages of saline-irrigation over solid-tip
ablation—minimization of surface damage with the concur-
rent creation of deeper lesions—it has not yet been proven
that saline irrigation will improve the outcome in RSDN.
Indeed, the high blood flow conditions of the renal arteries
may allow adequate ambient cooling of the ablation elec-
trode even with solid-tip nonirrigated ablation catheters.
Also, a chronic porcine study of RSDN using a solid-tip
radiofrequency energy catheter revealed no evidence of
intimal hyperplasia after 6 months (12). By contrast, in the
presence of atherosclerotic changes to the arterial wall,
saline irrigation may be required to generate an adequate
ablation lesion. Finally, though not seen in the present
series, the 8-F puncture required for the saline-irrigated
catheter is larger than the 6-F puncture needed for the
solid-tip catheter used in the Symplicity trials and may
potentiate more vascular access complications. Ultimately,
the role of saline irrigation for radiofrequency-based RSDN
should be explored further in randomized clinical trials.
Technical aspects of RSDN with the irrigated catheter. From
technical perspective, maneuvering the saline-irrigated
FA catheter into the renal arteries was somewhat difficult
ecause of the often acute, inferior angle of takeoff of the
enal arteries from the aorta. However, our data demon-
trate that it is both possible and safe to employ this catheter
o perform RSDN. This has been further verified in an
dditional 50 patients (V. Reddy and P. Neuzil, personal
ommunication, March 2012). By contrast, it is clear that a
atheter system designed for renal arterial access, such as
hat employed in the Symplicity studies, is technically
dvantageous—though future RFA catheters will likely
ncorporate a saline-irrigated ablative element.
Procedural outcome. Whereas the limited number of pa-
ients precludes robust conclusions from this study, all 10
atients underwent RSDN with the saline-irrigated RFA
atheter without any procedural complications. At 3 months
fter the procedure, there was no evidence of renal artery
tenosis or aneurysm. Additional follow-up in a larger
ohort of patients for a longer period is mandatory before
efinitively concluding this to be a safe approach for RSDN.
Similar to what was previously reported in the Symplicity
TN trials, the BP decrease from a baseline of 158 16/88 15
mm Hg was modest at 1 month (6/4 mm Hg, p 
0.002/p  0.02), but decreased more significantly at 3
months (22/13 mm Hg, p  0.0001/p  0.0001).
These blood pressure changes were sustained at 6 months
(21/11 mm Hg, p 0.003/p 0.005). This progressive
and sustained change indicates that the physiological effect
of RSDN is not immediate, but as previously noted, requires
a period of months to achieve its full effect. In addition, at
least for 6 months, there was no evidence of reinnervation.
This is consistent with prior data indicating an antihyper-
tensive effect that persists for at least 2 years (8).Regarding the magnitude of BP reduction, it is important
to recognize that the primary means for assessing BP change
in our study was 24-h ABPM. In Simplicity HTN-2, 24-h
ABPM was available for 20 and 25 patients in the RSDN
and control groups, respectively (8). It is interesting (though
ultimately inconclusive) that the magnitude of BP reduction
observed between baseline and 6 months in Simplicity
HTN-2 (11/7 vs. 3/1 mm Hg for the RSDN and
controls, respectively) was directionally consistent, but nu-
merically less than observed in the present study (21/11
mm Hg).
The mechanism for such a disparity could be related to:
1) differences in patient populations; 2) the ability of
saline-irrigation to project ablative energy deeper in tissue;
and 3) the larger electrode of the irrigated RFA catheter
might allow for greater coverage of the vessel perimeter,
thereby maximizing the effect of the RSDN procedure. This
might also explain why all patients in the present series
exhibited at least some BP drop—as compared to a 14% and
16% nonresponder rate in Symplicity HTN-1 and -2,
respectively (6,7). However, both the small number of
patients in the present study and the absence of a control
group mandate that we consider these data as merely
hypothesis generating and will ultimately require random-
ized clinical trial testing.
Venous sampling revealed significant decreases in meta-
nephrine, normetanephrine, and aldosterone levels. Because
metanephrine and normetanephrine are breakdown prod-
ucts of the neurotransmitters epinephrine and norepineph-
rine, their levels should decrease if kidney-central SNS axis
is modified. These changes are consistent with prior obser-
vations of a decrease in renal and total body norepinephrine
spillover and a decrease in muscle SNS activity (13). In
addition, the observation that aldosterone levels are also
statistically significantly decreased after RSDN is consistent
with an important effect on the renin-angiotensin-
aldosterone system. There was no statistically significant
change in plasma renin activity, but this may be due to the
small sample size. There were only a limited number of
patients in our series. Though not technically feasible, it
would have been preferable to determine the real-time rate
of neurohormone production (i.e., norepinephrine spill-
over). Still, these data add to the current body of literature
regarding the physiological impact of RSDN.
Study limitations. Despite observing a statistically signifi-
cant BP reduction even with the relatively small number of
patients included in this series, an important limitation of
this study was the lack of a placebo control. It has been well
described that when administering a placebo “treatment,”
the biofeedback pressure-lowering capability in hypertensive
individuals is both real and powerful. Therefore, despite the
concordance of our data with the Simplicity HTN studies,
it is impossible to rule out with absolute certainty that the
favorable effect on BP was not in part, or in whole, due to
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765the placebo effects of biofeedback. It is clear that a random-
ized controlled trial with a true placebo control, and ideally
of double-blind design, will be necessary to definitively
establish the efficacy of RSDN with the saline-irrigated
RFA catheter in refractory hypertension. Indeed, until such
definitive trials, we believe that procedures employing this
catheter for off-label use are best performed in the setting of
clinical registries.
Conclusions
RSDN can be performed safely and effectively in patients
with resistant hypertension, using an off-the-shelf saline-
irrigated RFA catheter. This feasibility experience provides
the scientific basis for future randomized controlled trials to
address both the scientific question of the safety and
effectiveness of RSDN in refractory hypertensive patients
in a placebo-controlled blinded manner and the technical
question as to relative safety and efficacy of solid-tip and
saline-irrigated RFA for RSDN.
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